Semaphorins 3A and 4D Levels in Heart Failure Patients

• Conditions: Heart Failure
• Interventions: Other: Biospecimen retention

• Registration Number: NCT02406716
• Lead Sponsor: Bnai Zion Medical Center

Brief Summary

This study hypothesis is that Semaphorins 3A and 4D levels are overexpressed in patients with heart failure. Study protocol:

Hospitallized patients with new onset or previously diagnosed heart failure will be recruited to the study. Control group will include healthy people with no medical records or chronic treatment at the same age range. After signing an informed constent form, full medical history and blood samples will be collected. A second blood sample will be collected 8 weeks later, assuming the patient was discharged and not hospitalized since than. The blood samples will be analyzed by Bnai Zion Medical Center Immunology labs for the above semaphorins levels in the heart failure group and control group. Statistical analysis will then commence for possible correlatoion with different clinical parameters.

Detailed Description

In few previous published studies, Semaphorins 3A levels are overexpressed in patients with heart failure. The aim of our study is the compare semaphorin 3A and 4D in patients with acute decompansated heart failure with healthy donors. Second aim is to compare semaphorin level in the same patients in time of hospitalization and few weeks later when the heart failure presumingly controled. Statistical analysis will then commense for possible correlatoion with different clinical parameters like NYHA (new york heart association) status of the patient, lenghts of hospitalization and BNP (brain natriuretic peptide) levels at time of admition.

Study Timeline

• Status Verified: 2015-03
• Study First Submitted: 2015-03-29
• Study First Submitted QC: 2015-03-30
• Last Update Submitted: 2015-03-30
• Study Start: 2015-04
• Study First Posted: 2015-04-02
• Last Update Posted: 2015-04-02
• Primary Completion: 2016-05
• Study Completion: 2017-05

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Patients with new onset or previously diagnosed heart failure.
• Heart failure diagnosis can be based on clinical judgment, echocardiography or elevated BNP levels

Exclusion Criteria

• Patients with acute myocardial infarction diagnosed clinicly and labratory

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Controls	Biospecimen retention	Healthy donors
HF	Biospecimen retention	Heart failure patients

Primary Outcome Measures

Name	Time	Method
Semaphrone 3A and 4D levels	one year

Secondary Outcome Measures

Name	Time	Method
BNP level	one year	Brain natriuretic peptide level in patient plasma